A
ASRT
vs
S&P 500
S&P 500
Over the past 12 months, ASRT has underperformed S&P 500, delivering a return of -27% compared to the S&P 500's +14% growth.
Stocks Performance
ASRT vs S&P 500
Performance Gap
ASRT vs S&P 500
Performance By Year
ASRT vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Assertio Holdings Inc
Glance View
Assertio Holdings, Inc. engages in the provision of commercial pharmaceutical products. The company is headquartered in Lake Forest, Illinois and currently employs 19 full-time employees. The firm's primary marketed products are INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, INDOCIN (indomethacin) Oral Suspension, CAMBIA (diclofenac potassium for oral solution), Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray and Zipsor (diclofenac potassium) Liquid filled capsules. The firm has other commercially available products, which include OXAYDO (oxycodone HCI, USP) tablets for oral use only. Assertio and Zyla are the registered trademarks of the Company. INDOCIN products are used for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease, moderate to severe ankylosing spondylitis, moderate to severe osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis.